文献速递淋巴瘤造血干细胞移植与细胞治疗

嵌合抗原受体T细胞疗法作为大B细胞淋巴瘤二线治疗优于标准治疗:系统综述与Meta分析

Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
PubMed 文献 · Br J Haematol · 2022-06-28

该系统综述与Meta分析纳入3项2021年发表的随机对照试验(共865例参与者),比较标准治疗与嵌合抗原受体T细胞(CAR-T)疗法用于12个月内复发或难治性大B细胞淋巴瘤(LBCL)的疗效与安全性。CAR-T组无事件生存期(HR 0.57,95%CI 0.49-0.68)和总生存期(HR 0.77,95%CI 0.60-0.98)均显著优于标准治疗,总缓解率更优(RR 1.55,95%CI 1.12-2.13,p=0.001),III/IV级不良事件风险两组相当(RR 1.03,95%CI 0.93-1.14)。

要点

  • CAR-T二线治疗12个月内复发或难治性LBCL,无事件生存期和总生存期均显著优于标准治疗。
  • CAR-T组总缓解率显著更优(RR 1.55,95%CI 1.12-2.13,p=0.001)。
  • 两组III/IV级不良事件风险相当(RR 1.03,95%CI 0.93-1.14)。

核心结论

  • 与标准治疗相比,CAR-T疗法用于12个月内复发或难治性LBCL患者具有更优的结局,且不增加毒性。
  • 需要更长的随访来确认这些结果并确定CAR-T疗法在LBCL管理中的最佳序贯方式。

研究设计与样本

  • 系统综述与Meta分析,纳入比较标准治疗与CAR-T疗法作为二线治疗的随机对照试验。
  • 纳入2021年发表的3项试验,共865例参与者。
  • 研究对象为12个月内复发或难治性LBCL患者。
  • 结局包括总生存期、无事件生存期、总缓解率和安全性。

主要发现

  • CAR-T组无事件生存期较标准治疗显著改善,HR 0.57(95%CI 0.49-0.68)。
  • CAR-T组总生存期较标准治疗显著改善,HR 0.77(95%CI 0.60-0.98)。
  • CAR-T组总缓解率显著更优,RR 1.55(95%CI 1.12-2.13,p=0.001)。
  • 两组III/IV级不良事件风险相当,RR 1.03(95%CI 0.93-1.14)。

临床怎么用

  • 原文结论指出CAR-T疗法在12个月内复发或难治性LBCL患者中结局优于标准治疗且不增加毒性。
  • 原文指出需要更长随访以确认结果并确定CAR-T疗法在LBCL管理中的最佳序贯方式。

局限性

  • 需要更长的随访来确认这些结果并确定CAR-T疗法在LBCL管理中的最佳序贯方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered standard of care (SOC) second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL). However, outcomes remain suboptimal. A systematic review and meta-analysis of randomised controlled trials comparing efficacy and safety of SOC versus chimeric antigen receptor T-cell (CAR-T) therapy as second-line for patients with LBCL refractory or relapsing within 12 months. Outcomes included overall survival (OS), event-free survival (EFS), overall response rate (ORR) and safety. Three trials published in 2021 (involving 865 participants) fulfilled the eligibility criteria. EFS as well as OS were significantly improved with CAR-T therapy as compared to SOC, hazard ratio (HR) 0.57 (95% confidence interval [CI] 0.49-0.68) and HR 0.77 (95% CI 0.60-0.98) respectively. CAR-T therapy was associated with significantly better ORR, relative risk (RR) 1.55 (95% CI 1.12-2.13, p = 0.001). The risk of Grade III/IV adverse event was comparable between the two arms, RR 1.03 (95% CI 0.93-1.14). In summary, CAR-T therapy has superior outcomes as compared to SOC in patients with LBCL refractory or relapsing within 12 months, without excess of toxicity. Longer follow-up is needed to confirm these results and determine the optimal sequencing of CAR-T therapy in the management of LBCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shargian L, Raanani P, Yeshurun M, et al. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis. Br J Haematol. 2022. PMID: 35765220. doi:10.1111/bjh.18335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。